Verrica Pharmaceuticals (VRCA) Retained Earnings (2021 - 2025)
Verrica Pharmaceuticals has reported Retained Earnings over the past 5 years, most recently at -$324.9 million for Q4 2025.
- Quarterly results put Retained Earnings at -$324.9 million for Q4 2025, down 5.82% from a year ago — trailing twelve months through Dec 2025 was -$324.9 million (down 5.82% YoY), and the annual figure for FY2025 was -$324.9 million, down 5.82%.
- Retained Earnings for Q4 2025 was -$324.9 million at Verrica Pharmaceuticals, down from -$316.8 million in the prior quarter.
- Over the last five years, Retained Earnings for VRCA hit a ceiling of -$1000.0 in Q2 2021 and a floor of -$324.9 million in Q4 2025.
- Median Retained Earnings over the past 5 years was -$193.4 million (2023), compared with a mean of -$195.5 million.
- Biggest five-year swings in Retained Earnings: crashed 15760300.0% in 2022 and later fell 5.82% in 2025.
- Verrica Pharmaceuticals' Retained Earnings stood at -$29000.0 in 2021, then plummeted by 563531.03% to -$163.5 million in 2022, then crashed by 40.99% to -$230.4 million in 2023, then tumbled by 33.23% to -$307.0 million in 2024, then fell by 5.82% to -$324.9 million in 2025.
- The last three reported values for Retained Earnings were -$324.9 million (Q4 2025), -$316.8 million (Q3 2025), and -$316.6 million (Q2 2025) per Business Quant data.